banner2

Getting started
2-Aminobenzenethiol

2-Aminobenzenethiol - China Manufacturers, Factory, Suppliers

2-Aminobenzenethiol, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

2-Aminothiophenol CAS 137-07-5 Purity 99.0 (GC) Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 2-Aminothiophenol CAS 137-07-5 Purity >99.0% (GC) Factory
Read More

Trimagnesium Dicitrate Nonahydrate CAS 153531-96-5 Magnesium (Mg) 14.5%~16.4%

Saccharin Insoluble CAS 81-07-2 Purity >99.0% (HPLC)

2,3-Butanedione CAS 431-03-8 Purity >99.0% (GC)

Citric Acid Anhydrous CAS 77-92-9 Assay 99.5~100.5%

Dimethyl Dicarbonate (DMPC) CAS 4525-33-1 Purity ≥99.8% (HPLC) Food Additive Preservative

Maltol CAS 118-71-8 (3-Hydroxy-2-Methyl-4-Pyrone) Purity ≥99.0% (HPLC)

banner1

Top Selling Products

Related Blog
Reviews

Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
The 3rd China International Biological & Chemical Pharmaceutical Industry Conference

The 3rd CMC-China 2021 Time: September 29-30, 2021 Exhibition Venue: C-D Hall, Suzhou International Expo Center, Suzhou City, JIangsu Province, China. Synergy of Centralized China’s Drug Volume-ba...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...

2022.06.10 03:27:27
2022.04.30 02:50:12
2022.01.18 03:14:42
2022.01.10 02:19:22
2021.12.25 02:04:36
2021.12.21 02:14:53

related search